Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004
Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Vasoactive intestinal peptide (VIP) supresses ACE2- and TMPRSS2 expression in stimulated epithelial cells Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001
Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002
VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
The vasoactive effects of helospectins I and II in vivo are not mediated by VIP and PACAP1-38 receptors or vasodilator prostaglandins Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006
Protection of vasoconstriction and lung function impairment by endothelin-receptor blockers and vasoactive intestinal peptide (VIP) in isolated perfused rat lungs Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008
Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea Source: Eur Respir J 2003; 21: 3-10 Year: 2003
Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005
Immunohistochemical relationship between transient receptor potential vanilloid-1 (TRPV1) and neuropeptide (CGRP, Substance P) in the guinea pig respiratory system Source: Eur Respir J 2005; 26: Suppl. 49, 364s Year: 2005
Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007
Vasoactive and growth factors in pulmonary emphysema Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD Year: 2010
N-formyl Met-Leu-Phe (fMLP), a microbe-derived chemoattractant for leukocytes, activates porcine airway submucosal gland acinar cells Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Neuropeptide regulation of secretion and inflammation in human airway gland serous cells Source: Eur Respir J, 55 (4) 1901386; 10.1183/13993003.01386-2019 Year: 2020